Nencini P, Valeri P
Institute of Medical Pharmacology, University of Rome La Sapienza, Italy.
Pharmacol Biochem Behav. 1994 May;48(1):63-8. doi: 10.1016/0091-3057(94)90499-5.
The influences of the kappa-opiate agonist U50,488H (U50; 4 mg/kg IP), the neuroleptic haloperidol (HAL; 0.3 mg/kg IP), and MK-801 (0.2 mg/kg IP), a noncompetitive antagonist for NMDA receptors, were compared on the effects of nine days of d-amphetamine (AMPH) treatment (3 mg/kg IP) on food and water intake and urine output. AMPH prevented feeding stimulation produced by U50 during the first 2 h, whereas U50 inhibited the hyperphagic phase that rats showed between 2 and 5 h after AMPH administration. Tolerance did not develop to the first 2-h suppression of feeding; in contrast, the late hyperphagic phase slowly recovered across the nine days of treatment. Combined administration of the two drugs barely affected water intake but considerably increased urine output. Unlike U50, HAL left the late hyperphagic response to AMPH unchanged and delayed the development of hyperdipsia. In our study MK-801 had one effect only: It significantly reduced amphetamine diuresis. These results suggest that by inhibiting the late hyperphagic response U50 enhances the anorectic effects of AMPH, but that dopamine probably has no direct role in this interaction.
比较了κ-阿片受体激动剂U50,488H(U50;4毫克/千克腹腔注射)、抗精神病药物氟哌啶醇(HAL;0.3毫克/千克腹腔注射)和NMDA受体非竞争性拮抗剂MK-801(0.2毫克/千克腹腔注射)对9天右旋苯丙胺(AMPH)治疗(3毫克/千克腹腔注射)对食物和水摄入量及尿量的影响。在最初2小时内,AMPH可预防U50产生的进食刺激,而U50可抑制大鼠在AMPH给药后2至5小时出现的贪食期。对最初2小时的进食抑制未产生耐受性;相反,在9天的治疗过程中,后期贪食期缓慢恢复。两种药物联合给药对水摄入量几乎没有影响,但显著增加了尿量。与U50不同,HAL对AMPH的后期贪食反应没有影响,并延迟了烦渴的发展。在我们的研究中,MK-801只有一种作用:它显著降低了苯丙胺利尿作用。这些结果表明,U50通过抑制后期贪食反应增强了AMPH的厌食作用,但多巴胺可能在这种相互作用中没有直接作用。